| Literature DB >> 34943730 |
Magdalena Monika Gruber1,2, Alexandra Weber1,2, Jette Jung1,3, Jens Werner4, Rika Draenert1.
Abstract
BACKGROUND: Antibiotic stewardship (AS) ward rounds are a core element in clinical care for surgical patients. Therefore, we aimed to analyze the impact of surgical AS ward rounds on antibiotic prescribing, and the sustainability of the effect after the AS interventions are no longer provided.Entities:
Keywords: antibiotic consumption; antibiotic stewardship; sustainability; visceral surgery
Year: 2021 PMID: 34943730 PMCID: PMC8698864 DOI: 10.3390/antibiotics10121518
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Flow chart of all patients admitted to four wards of the visceral surgery department during P1 and P2.
Patient characteristics and descriptive data for all patients included, comparing P1 and P2.
| Characteristics | P1 ( | P2 ( | |
|---|---|---|---|
| Age—years, median (range) | 62 (18–96) | 62 (20–98) | 0.809 |
| Sex, female—no. (%) | 110 (36.8) | 126 (45.8) | 0.028 |
| Charlson comorbidity index—median (range) | 2 (0–8) | 2 (0–10) | 0.637 |
| Penicillin allergy—no. (%) | 23 (7.7) | 19 (6.9) | 0.719 |
| Diagnosis—no. (%) | 0.948 | ||
| Bowel | 127 (42.5) | 112 (40.7) | 0.671 |
| Liver | 61 (20.4) | 53 (19,3) | 0.735 |
| Pancreas | 29 (9.7) | 31 (11,3) | 0.538 |
| Skin and soft tissue | 22 (7.4) | 23 (8.4) | 0.654 |
| Others | 60 (20.1) | 56 (20.4) | 0.930 |
| No surgery | 87 (29.1) | 62 (22.5) | 0.074 |
| ICU—no. (%) | 31 (10.4) | 35 (12.7) | 0.376 |
| Length of hospital stay—days, median (range) | 14 (2–90) | 15 (2–79) | 0.677 |
| In-hospital mortality—no. (%) | 3 (1.0) | 2 (0.7) | 0.722 |
| Rate of readmission for infection after 30 days—no. (%) | 25 (8.4) | 20 (7.3) | 0.621 |
| Length of therapy (LOT)—days, median (range) | 8 (1–73) | 8 (1–77) | 0.814 |
| LOT < 5 d—no. (%) | 50 (16.7) | 45 (16.4) | 0.908 |
| LOT 5–9 d—no. (%) | 121 (40.5) | 108 (39.3) | 0.770 |
| LOT 10–14 d—no. (%) | 47 (15.7) | 55 (20.0) | 0.180 |
| LOT ≥ 15 d—no. (%) | 81 (27.1) | 67 (24.4) | 0.456 |
| Multidrug-resistant bacteria | |||
| gram-positive | 6 | 6 | 0.884 |
| gram-negative | 9 | 10 | 0.675 |
Figure 2Overall antibiotic consumption, and consumption of ciprofloxacin, linezolid, meropenem, and piperacillin/tazobactam on the four wards, comparing P1 and P2.
Changes in antibiotic therapy for all courses of antibiotics, comparing P1 and P2.
| W1/2 | W3 | W4 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| P1 a | P2 a | P1 | P2 a | P1 a | P2 | ||||
| Courses of antibiotics | 113 | 90 | 130 | 120 | 99 | 102 | |||
| Route of antibiotics at beginning of | 0.425 | 0.649 | 0.941 | ||||||
| Intravenous | 99 (87.6) | 82 (91.1) | 117 (90.0) | 110 (91.7) | 88 (88.9) | 91 (89.2) | |||
| Oral | 14 (12.4) | 8 (8.9) | 13 (10.0) | 10 (8.3) | 11 (11.1) | 11 (10.8) | |||
| iv-to-oral switch | 42 (42.4) | 36 (43.9) | 0.842 | 41 (35.0) | 37 (33.6) | 0.824 | 26 (29.5) | 19 (20.9) | 0.181 |
| De-escalation | 29 (25.7) | 36 (40.0) | 0.030 | 20 (15.4) | 29 (24.2) | 0.081 | 20 (20.2) | 16 (15.7) | 0.404 |
| Escalation | 43 (38.1) | 32 (35.6) | 0.714 | 35 (26.9) | 22 (18.3) | 0.106 | 25 (25.3) | 19 (18.6) | 0.256 |
| Duration to iv-to-oral switch—days, median (range) | 6 (1–21) | 6 (1–15) | 0.757 | 5 (1–20) | 6.5 (1–20) | 0.722 | 5 (2–13) | 4 (2–28) | 0.649 |
| Duration to de-escalation—days, median (range) | 6 (1–21) | 6 (1–15) | 0.738 | 5.5 (1–29) | 6.5 (2–20) | 0.674 | 6.5 (1–16) | 5 (2–21) | 0.809 |
a AS Intervention, b Courses of antibiotics with more than one iv-to-oral switch/de-escalation were excluded from this statistical analysis.
Figure 3Study timeline of AS intervention and prescribing analysis for the four wards.
Antibiotic ranking [30].
| Rank 1 | narrow spectrum penicillins, first- and second-generation cephalosporins, co-trimoxazole, doxycycline, oral fosfomycin, metronidazole |
| Rank 2 | aminopenicillin/beta-lactamase inhibitor, third-generation cephalosporins, fluoroquinolones, macrolides, clindamycin |
| Rank 3 | fourth-generation cephalosporines, carbapenems, piperacillin/tazobactam, vancomycin |
| Rank 4 | daptomycin, linezolid, tigecycline |